Acadia Pharmaceuticals (ACAD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.02+0.57%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Acadia focuses on drugs for brain disorders with steady sales growth. Management aims for revenue near $1.28 billion in 2026. Costs are controlled with SG&A capped at $700 million. Positive EU drug reviews support future sales.
Earnings missed recently and guidance was cut, showing risks. Revenue growth may slow below 10%. High profit multiples suggest the stock is expensive if growth falters.
The stock trades about 16% above our fair value near $16. Analysts expect about 18% revenue growth, which is optimistic versus recent guidance cuts.
Breaks if: Negative regulatory decisions or loss of approvals
Breaks if: Annual revenue falls below $1.22 billion in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a durable compounder with a focus on consistent revenue growth and clinical advancements. The current thesis state is intact, supported by strong recent financial performance and a favorable sector backdrop.
The market appears to have priced in a neutral valuation, with a slight premium compared to peers. There is a low expectations gap, indicating that the current performance is largely justified by market sentiment.
Fundamentals are likely to continue showing robust earnings quality and strong revenue growth, especially if management maintains guidance and controls expenses. However, there is a moderate risk due to potential economic headwinds that could impact performance.
The long-term thesis hinges on management's ability to reaffirm revenue guidance and advance clinical development for key products. Additionally, broader sector performance and economic indicators will significantly influence outcomes.
The most important moves since the prior daily snapshot.
Yes, our read has strengthened. The latest earnings beat supports this improved outlook. There are no new threats identified that could weaken the thesis.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Maintain and update full year 2026 revenue guidance reflecting growth in DAYBUE and NUPLAZID sales.
Stated as a priority in 3 of last 3 quarters. GAAP total revenues grew from $1.07 billion in 2025 to $308 million in 2026-Q2 (16% YoY growth in Q2). Management increased 2026 full year revenue guidance from $1.22-$1.28 billion to $1.24-$1.30 billion in 2026-Q2, reflecting growth in DAYBUE and reaffirmed NUPLAZID sales. The trajectory is delivering consistent revenue growth and updated guidance.
“Increased full year 2026 total revenue guidance to $1.24 to $1.30 billion”
“Reaffirms full year guidance and remain confident in ability to deliver long-term value”
“Full year 2026 guidance for total revenues of $1.22 to $1.28 billion”
Breaks if: SG&A expenses exceed $700 million in FY26
Maintain selling, general and administrative expenses within guided range to support growth while managing costs.
Stated as a priority in 3 of last 3 quarters. SG&A expenses rose from $134 million in 2025-Q2 to $160 million in 2026-Q2, reflecting increased investments to support growth. Management maintained full year 2026 SG&A guidance at $660 to $700 million consistently. The trajectory shows increased spending aligned with growth support but within guided range.
“SG&A expense in the range of $660 to $700 million”
“SG&A expense in the range of $660 to $700 million”
“SG&A expense in the range of $660 to $700 million”
Over the next 1 to 3 years, ACAD's performance will depend on its execution of growth strategies and external market conditions. Not investment advice.